Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings: A Systematic Review and Meta-analysis | Research, Methods, Statistics | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Mann  K, Schäfer  DR, Längle  G, Ackermann  K, Croissant  B.  The long-term course of alcoholism, 5, 10 and 16 years after treatment.  Addiction. 2005;100(6):797-805.PubMedGoogle ScholarCrossref
2.
Norström  T.  Per capita alcohol consumption and all-cause mortality in Canada, 1950-98.  Addiction. 2004;99(10):1274-1278.PubMedGoogle ScholarCrossref
3.
Rivara  FP, Garrison  MM, Ebel  B, McCarty  CA, Christakis  DA.  Mortality attributable to harmful drinking in the United States, 2000.  J Stud Alcohol. 2004;65(4):530-536.PubMedGoogle Scholar
4.
National Collaborating Centre for Mental Health.  Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence: National Clinical Practice Guideline 115. London, England: National Institute for Health & Clinical Excellence; 2011.
5.
Schuckit  MA.  Alcohol-use disorders.  Lancet. 2009;373(9662):492-501.PubMedGoogle ScholarCrossref
6.
Hasin  DS, Stinson  FS, Ogburn  E, Grant  BF.  Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.  Arch Gen Psychiatry. 2007;64(7):830-842.PubMedGoogle ScholarCrossref
7.
Mertens  JR, Weisner  C, Ray  GT, Fireman  B, Walsh  K.  Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions, and costs.  Alcohol Clin Exp Res. 2005;29(6):989-998.PubMedGoogle ScholarCrossref
8.
Teesson  M, Baillie  A, Lynskey  M, Manor  B, Degenhardt  L.  Substance use, dependence and treatment seeking in the United States and Australia: a cross-national comparison.  Drug Alcohol Depend. 2006;81(2):149-155.PubMedGoogle ScholarCrossref
9.
Jonas  DE, Amick  HR, Feltner  C,  et al. Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings. Comparative Effectiveness Review No. 134. (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract 290-2012-00008-I.) AHRQ publication 14-EHC029-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2014.
10.
Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality. http://effectivehealthcare.ahrq.gov/ehc/products/60/318/CER-Methods-Guide-140109.pdf. Accessed April 21, 2014.
11.
Viswanathan  M, Ansari  MT, Berkman  ND,  et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Rockville, MD: Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. AHRQ publication 12-EHC047-EF. http://www.ncbi.nlm.nih.gov/books/NBK91433/pdf/cerguidebias.pdf. Accessed April 21, 2014.
12.
Sutton  AJ, Abrams  KR, Jones  DR,  et al.  Methods for Meta-Analysis in Medical Research [Wiley Series in Probability and Statistics: Applied Probability and Statistics Section]. London, England: Wiley; 2000.
13.
Higgins  JP, Thompson  SG.  Quantifying heterogeneity in a meta-analysis.  Stat Med. 2002;21(11):1539-1558.PubMedGoogle ScholarCrossref
14.
Higgins  JP, Thompson  SG, Deeks  JJ, Altman  DG.  Measuring inconsistency in meta-analyses.  BMJ. 2003;327(7414):557-560.PubMedGoogle ScholarCrossref
15.
Ioannidis  JP, Trikalinos  TA.  The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey.  CMAJ. 2007;176(8):1091-1096.PubMedGoogle ScholarCrossref
16.
Higgins  JPT, Green  S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]: 10.4.1: Funnel plots. http://handbook.cochrane.org/chapter_10/10_4_1_funnel_plots.htm. Accessed April 16, 2014.
17.
Begg  CB, Mazumdar  M.  Operating characteristics of a rank correlation test for publication bias.  Biometrics. 1994;50(4):1088-1101.PubMedGoogle ScholarCrossref
18.
Owens  DK, Lohr  KN, Atkins  D,  et al.  AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions: Agency for Healthcare Research and Quality and the effective health-care program.  J Clin Epidemiol. 2010;63(5):513-523.PubMedGoogle ScholarCrossref
19.
Barrias  JA, Chabac  S, Ferreira  L, Fonte  A, Potgieter  A, Teixeira de Sousa  E.  Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study [in Portuguese].  Psiquiatria Clinica. 1997;18:149-160.Google Scholar
20.
Huang  X, Huang  X, Peng  H, Mai  G. Placebo-controlled trial of naltrexone in outpatient treatment of alcohol dependence [in Chinese].  Chin Ment Health J.2002;16(5):302-303.Google Scholar
21.
Krupitski  EM, Burakov  AM, Ivanov  VB,  et al.  The use of baclofen for treating affective disorders in alcoholism [in Russian].  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinsko. 1994;94(1):57-61.Google Scholar
22.
Ladewig  D, Knecht  T, Leher  P, Fendl  A.  Acamprosate: a stabilizing factor in long-term withdrawal of alcoholic patients [in German].  Ther Umsch. 1993;50(3):182-188.PubMedGoogle Scholar
23.
Castro  LA, Laranjeira  R.  A double blind, randomized and placebo-controlled clinical trial with naltrexone and brief intervention in outpatient treatment of alcohol dependence [in Portuguese].  J Bras Psiquiatr. 2009;58(2):79-85.Google ScholarCrossref
24.
Roussaux  JP, Hers  D, Ferauge  M.  Does acamprosate diminish the appetite for alcohol in weaned alcoholics? [in French].  J Pharm Belg. 1996;51(2):65-68.PubMedGoogle Scholar
25.
Geerlings  P, Ansoms  C, Van  DBW.  Acamprosate and relapse prevention in outpatient alcoholics: results from a randomized, placebo-controlled double-blind study in the Benelux.  Tijdschrift Voor Alcohol Drugs En Andere Psychotrope Stoffen. 1995;21(3):129-141.Google Scholar
26.
Kiefer  F, Jahn  H, Holzbach  R,  et al.  The NALCAM study: efficacy, tolerability, outcome.  Sucht. 2003;49(6):342-351.Google Scholar
27.
Sass  H, Mann  K, Soyka  M.  Drug support for prevention of relapse in alcoholic patients with acamprosate: results of a double blind, randomized, placebo controlled study.  Sucht. 1996;42(5):316-322.Google Scholar
28.
Sass  H, Soyka  M, Mann  K, Zieglgänsberger  W.  Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence.  Arch Gen Psychiatry. 1996;53(8):673-680.PubMedGoogle ScholarCrossref
29.
Narayama  PL, Gupta  AK, Sharma  PK.  Use of anti-craving agents in soldiers with alcohol dependence syndrome.  Med J Armed Forces India. 2008;64(4):320-324.Google ScholarCrossref
30.
Anton  RF, O’Malley  SS, Ciraulo  DA,  et al; COMBINE Study Research Group.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.  JAMA. 2006;295(17):2003-2017.PubMedGoogle ScholarCrossref
31.
Fuller  RK, Roth  HP.  Disulfiram for the treatment of alcoholism: an evaluation in 128 men.  Ann Intern Med. 1979;90(6):901-904.PubMedGoogle ScholarCrossref
32.
Fuller  RK, Branchey  L, Brightwell  DR,  et al.  Disulfiram treatment of alcoholism: a Veterans Administration cooperative study.  JAMA. 1986;256(11):1449-1455.PubMedGoogle ScholarCrossref
33.
LoCastro  JS, Youngblood  M, Cisler  RA,  et al.  Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study.  J Stud Alcohol Drugs. 2009;70(2):186-196.PubMedGoogle Scholar
34.
Morgenstern  J, Kuerbis  AN, Chen  AC, Kahler  CW, Bux  DA  Jr, Kranzler  HR.  A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.  J Consult Clin Psychol. 2012;80(5):863-875.PubMedGoogle ScholarCrossref
35.
Pettinati  HM, Gastfriend  DR, Dong  Q, Kranzler  HR, O’Malley  SS.  Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.  Alcohol Clin Exp Res. 2009;33(2):350-356.PubMedGoogle ScholarCrossref
36.
O’Malley  SS, Robin  RW, Levenson  AL,  et al.  Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.  Alcohol Clin Exp Res. 2008;32(7):1271-1283.PubMedGoogle ScholarCrossref
37.
Mason  BJ, Goodman  AM, Chabac  S, Lehert  P.  Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.  J Psychiatr Res. 2006;40(5):383-393.PubMedGoogle ScholarCrossref
38.
Morley  KC, Teesson  M, Reid  SC,  et al.  Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial.  Addiction. 2006;101(10):1451-1462.PubMedGoogle ScholarCrossref
39.
Kiefer  F, Jahn  H, Tarnaske  T,  et al.  Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.  Arch Gen Psychiatry. 2003;60(1):92-99.PubMedGoogle ScholarCrossref
40.
Mann  K, Lemenager  T, Hoffmann  S,  et al; PREDICT Study Team.  Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.  Addict Biol. 2013;18(6):937-946.PubMedGoogle ScholarCrossref
41.
Mason  BJ, Salvato  FR, Williams  LD, Ritvo  EC, Cutler  RB.  A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.  Arch Gen Psychiatry. 1999;56(8):719-724.PubMedGoogle ScholarCrossref
42.
Brady  KT, Myrick  H, Henderson  S, Coffey  SF.  The use of divalproex in alcohol relapse prevention: a pilot study.  Drug Alcohol Depend. 2002;67(3):323-330.PubMedGoogle ScholarCrossref
43.
Salloum  IM, Cornelius  JR, Daley  DC, Kirisci  L, Himmelhoch  JM, Thase  ME.  Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.  Arch Gen Psychiatry. 2005;62(1):37-45.PubMedGoogle ScholarCrossref
44.
Garbutt  JC, Kranzler  HR, O’Malley  SS,  et al; Vivitrex Study Group.  Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.  JAMA. 2005;293(13):1617-1625.PubMedGoogle ScholarCrossref
45.
Gual  A, Lehert  P.  Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain.  Alcohol Alcohol. 2001;36(5):413-418.PubMedGoogle ScholarCrossref
46.
Berger  L, Fisher  M, Brondino  M,  et al.  Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study.  Alcohol Clin Exp Res. 2013;37(4):668-674.PubMedGoogle ScholarCrossref
47.
Baltieri  DA, De Andrade  AG.  Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting.  J Stud Alcohol. 2004;65(1):136-139.PubMedGoogle Scholar
48.
Besson  J, Aeby  F, Kasas  A, Lehert  P, Potgieter  A.  Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.  Alcohol Clin Exp Res. 1998;22(3):573-579.PubMedGoogle ScholarCrossref
49.
Chick  J, Howlett  H, Morgan  MY, Ritson  B.  United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol.  Alcohol Alcohol. 2000;35(2):176-187.PubMedGoogle ScholarCrossref
50.
Chick  J, Anton  R, Checinski  K,  et al.  A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.  Alcohol Alcohol. 2000;35(6):587-593.PubMedGoogle ScholarCrossref
51.
Geerlings  PJ, Ansoms  C, Van Den Brink  W.  Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg.  Eur Addict Res. 1997;3(3):129-137.Google ScholarCrossref
52.
Paille  FM, Guelfi  JD, Perkins  AC, Royer  RJ, Steru  L, Parot  P.  Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol.  Alcohol Alcohol. 1995;30(2):239-247.PubMedGoogle Scholar
53.
Pelc  I, Verbanck  P, Le Bon  O, Gavrilovic  M, Lion  K, Lehert  P.  Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study.  Br J Psychiatry. 1997;171:73-77.PubMedGoogle ScholarCrossref
54.
Poldrugo  F.  Acamprosate treatment in a long-term community-based alcohol rehabilitation programme.  Addiction. 1997;92(11):1537-1546.PubMedGoogle ScholarCrossref
55.
Tempesta  E, Janiri  L, Bignamini  A, Chabac  S, Potgieter  A.  Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study.  Alcohol Alcohol. 2000;35(2):202-209.PubMedGoogle ScholarCrossref
56.
Whitworth  AB, Fischer  F, Lesch  OM,  et al.  Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.  Lancet. 1996;347(9013):1438-1442.PubMedGoogle ScholarCrossref
57.
Oslin  DW, Lynch  KG, Pettinati  HM,  et al.  A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.  Alcohol Clin Exp Res. 2008;32(7):1299-1308.PubMedGoogle ScholarCrossref
58.
Pettinati  HM, Oslin  DW, Kampman  KM,  et al.  A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.  Am J Psychiatry. 2010;167(6):668-675.PubMedGoogle ScholarCrossref
59.
Anton  RF, Moak  DH, Waid  LR, Latham  PK, Malcolm  RJ, Dias  JK.  Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.  Am J Psychiatry. 1999;156(11):1758-1764.PubMedGoogle Scholar
60.
Balldin  J, Berglund  M, Borg  S,  et al.  A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence.  Alcohol Clin Exp Res. 2003;27(7):1142-1149.PubMedGoogle ScholarCrossref
61.
Gastpar  M, Bonnet  U, Böning  J,  et al.  Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study.  J Clin Psychopharmacol. 2002;22(6):592-598.PubMedGoogle ScholarCrossref
62.
Guardia  J, Caso  C, Arias  F,  et al.  A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial.  Alcohol Clin Exp Res. 2002;26(9):1381-1387.PubMedGoogle ScholarCrossref
63.
Killeen  TK, Brady  KT, Gold  PB,  et al.  Effectiveness of naltrexone in a community treatment program.  Alcohol Clin Exp Res. 2004;28(11):1710-1717.PubMedGoogle ScholarCrossref
64.
Krystal  JH, Cramer  JA, Krol  WF, Kirk  GF, Rosenheck  RA; Veterans Affairs Naltrexone Cooperative Study 425 Group.  Naltrexone in the treatment of alcohol dependence.  N Engl J Med. 2001;345(24):1734-1739.PubMedGoogle ScholarCrossref
65.
Morris  PL, Hopwood  M, Whelan  G, Gardiner  J, Drummond  E.  Naltrexone for alcohol dependence: a randomized controlled trial.  Addiction. 2001;96(11):1565-1573.PubMedGoogle ScholarCrossref
66.
O’Malley  SS, Jaffe  AJ, Chang  G, Schottenfeld  RS, Meyer  RE, Rounsaville  B.  Naltrexone and coping skills therapy for alcohol dependence: a controlled study.  Arch Gen Psychiatry. 1992;49(11):881-887.PubMedGoogle ScholarCrossref
67.
O’Malley  SS, Sinha  R, Grilo  CM,  et al.  Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.  Alcohol Clin Exp Res. 2007;31(4):625-634.PubMedGoogle Scholar
68.
Oslin  D, Liberto  JG, O’Brien  J, Krois  S, Norbeck  J.  Naltrexone as an adjunctive treatment for older patients with alcohol dependence.  Am J Geriatr Psychiatry. 1997;5(4):324-332.PubMedGoogle ScholarCrossref
69.
Petrakis  IL, Poling  J, Levinson  C, Nich  C, Carroll  K, Rounsaville  B; VA New England VISN I MIRECC Study Group.  Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.  Biol Psychiatry. 2005;57(10):1128-1137.PubMedGoogle ScholarCrossref
70.
Volpicelli  JR, Rhines  KC, Rhines  JS, Volpicelli  LA, Alterman  AI, O’Brien  CP.  Naltrexone and alcohol dependence: role of subject compliance.  Arch Gen Psychiatry. 1997;54(8):737-742.PubMedGoogle ScholarCrossref
71.
Kranzler  HR, Wesson  DR, Billot  L; DrugAbuse Sciences Naltrexone Depot Study Group.  Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial.  Alcohol Clin Exp Res. 2004;28(7):1051-1059.PubMedGoogle ScholarCrossref
72.
Anton  RF, Moak  DH, Latham  P,  et al.  Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence.  J Clin Psychopharmacol. 2005;25(4):349-357.PubMedGoogle ScholarCrossref
73.
Wölwer  W, Frommann  N, Jänner  M,  et al.  The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial.  Drug Alcohol Depend. 2011;118(2-3):417-422.PubMedGoogle ScholarCrossref
74.
Latt  NC, Jurd  S, Houseman  J, Wutzke  SE.  Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting.  Med J Aust. 2002;176(11):530-534.PubMedGoogle Scholar
75.
Monti  PM, Rohsenow  DJ, Swift  RM,  et al.  Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.  Alcohol Clin Exp Res. 2001;25(11):1634-1647.PubMedGoogle ScholarCrossref
76.
ALK21-014: Efficacy and safety of Medisorb naltrexone (Vivitrol) after enforced abstinence; 2011. http://www.clinicaltrials.gov/ct2/show/NCT00501631. Accessed April 22, 2014.
77.
Johnson  BA, Rosenthal  N, Capece  JA,  et al; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group.  Topiramate for treating alcohol dependence: a randomized controlled trial.  JAMA. 2007;298(14):1641-1651.PubMedGoogle ScholarCrossref
78.
Kampman  KM, Pettinati  HM, Lynch  KG, Spratt  K, Wierzbicki  MR, O’Brien  CP.  A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence.  Drug Alcohol Depend. 2013;133(1):94-99.PubMedGoogle ScholarCrossref
79.
Johnson  BA, Ait-Daoud  N, Bowden  CL,  et al.  Oral topiramate for treatment of alcohol dependence: a randomised controlled trial.  Lancet. 2003;361(9370):1677-1685.PubMedGoogle ScholarCrossref
80.
Gual  A, He  Y, Torup  L, van den Brink  W, Mann  K; ESENSE 2 Study Group.  A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.  Eur Neuropsychopharmacol. 2013;23(11):1432-1442.PubMedGoogle ScholarCrossref
81.
Mann  K, Bladström  A, Torup  L, Gual  A, van den Brink  W.  Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.  Biol Psychiatry. 2013;73(8):706-713.PubMedGoogle ScholarCrossref
82.
Anton  RF, Pettinati  H, Zweben  A,  et al.  A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence.  J Clin Psychopharmacol. 2004;24(4):421-428.PubMedGoogle ScholarCrossref
83.
Karhuvaara  S, Simojoki  K, Virta  A,  et al.  Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.  Alcohol Clin Exp Res. 2007;31(7):1179-1187.PubMedGoogle ScholarCrossref
84.
Revia (naltrexone hydrochloride) [package insert]. Pomona, NY: Duramed Pharmaceuticals; 2009.
85.
Corrao  G, Bagnardi  V, Zambon  A, La Vecchia  C.  A meta-analysis of alcohol consumption and the risk of 15 diseases.  Prev Med. 2004;38(5):613-619.PubMedGoogle ScholarCrossref
86.
Jonas  DE, Garbutt  JC, Amick  HR,  et al.  Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the US Preventive Services Task Force.  Ann Intern Med. 2012;157(9):645-654.PubMedGoogle ScholarCrossref
87.
Rehm  J, Baliunas  D, Borges  GL,  et al.  The relation between different dimensions of alcohol consumption and burden of disease: an overview.  Addiction. 2010;105(5):817-843.PubMedGoogle ScholarCrossref
88.
Bondy  SJ, Rehm  J, Ashley  MJ, Walsh  G, Single  E, Room  R.  Low-risk drinking guidelines: the scientific evidence.  Can J Public Health. 1999;90(4):264-270.PubMedGoogle Scholar
89.
Shalala  DE. 10th Special Report to the US Congress on Alcohol and Health: Highlights From Current Research: From the Secretary of Health and Human Services. http://pubs.niaaa.nih.gov/publications/10report/intro.pdf. Accessed April 21, 2014.
90.
Centers for Disease Control and Prevention (CDC).  Alcohol-attributable deaths and years of potential life lost: United States, 2001.  MMWR Morb Mortal Wkly Rep. 2004;53(37):866-870.PubMedGoogle Scholar
91.
Cherpitel  CJ, Ye  Y.  Alcohol-attributable fraction for injury in the US general population: data from the 2005 National Alcohol Survey.  J Stud Alcohol Drugs. 2008;69(4):535-538.PubMedGoogle Scholar
92.
Rehm  J, Shield  KD, Gmel  G, Rehm  MX, Frick  U.  Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union.  Eur Neuropsychopharmacol. 2013;23(2):89-97.PubMedGoogle ScholarCrossref
93.
Zarkin  GA, Bray  JW, Aldridge  A,  et al.  The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.  Med Care. 2010;48(5):396-401.PubMedGoogle ScholarCrossref
94.
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders.5th ed. Washington, DC: American Psychiatric Association; 2013.
95.
Hasin  DS, O’Brien  CP, Auriacombe  M,  et al.  DSM-5 criteria for substance use disorders: recommendations and rationale.  Am J Psychiatry. 2013;170(8):834-851.PubMedGoogle ScholarCrossref
96.
Kranzler  HR, Armeli  S, Tennen  H,  et al.  Targeted naltrexone for early problem drinkers.  J Clin Psychopharmacol. 2003;23(3):294-304.PubMedGoogle Scholar
97.
Moyer  VA; Preventive Services Task Force.  Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: US Preventive Services Task Force recommendation statement.  Ann Intern Med. 2013;159(3):210-218.PubMedGoogle Scholar
98.
Jonas  DE, Garbutt  JC, Brown  JM,  et al. Screening, Behavioral Counseling, and Referral in Primary Care to Reduce Alcohol Misuse: Comparative Effectiveness Review No. 64: AHRQ publication 12-EHC055-EF. http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=1135&pageaction=displayproduct. Accessed April 16, 2014.
99.
O’Connor  PG.  Managing substance dependence as a chronic disease: is the glass half full or half empty?  JAMA. 2013;310(11):1132-1134.PubMedGoogle ScholarCrossref
100.
Harris  AH, Kivlahan  DR, Bowe  T, Humphreys  KN.  Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.  Psychiatr Serv. 2010;61(4):392-398.PubMedGoogle ScholarCrossref
101.
Harris  AH, Oliva  E, Bowe  T, Humphreys  KN, Kivlahan  DR, Trafton  JA.  Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence.  Psychiatr Serv. 2012;63(7):679-685.PubMedGoogle ScholarCrossref
102.
Pettinati  HM, Weiss  RD, Miller  WR, Donovan  D, Ernst  DB, Rounsaville  BJ.  Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence: COMBINE Monograph Series. Vol 2. DHHS publication (NIH) 04–5289. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004.
103.
Kiritzé-Topor  P, Huas  D, Rosenzweig  C, Comte  S, Paille  F, Lehert  P.  A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care.  Alcohol Alcohol. 2004;39(6):520-527.PubMedGoogle ScholarCrossref
104.
O’Malley  SS, Rounsaville  BJ, Farren  C,  et al.  Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.  Arch Intern Med. 2003;163(14):1695-1704.PubMedGoogle ScholarCrossref
105.
Oslin  DW, Lynch  KG, Maisto  SA,  et al.  A randomized clinical trial of alcohol care management delivered in Department of Veterans Affairs primary care clinics versus specialty addiction treatment.  J Gen Intern Med. 2014;29(1):162-168.PubMedGoogle ScholarCrossref
106.
Saitz  R, Cheng  DM, Winter  M,  et al.  Chronic care management for dependence on alcohol and other drugs: the AHEAD randomized trial.  JAMA. 2013;310(11):1156-1167.PubMedGoogle ScholarCrossref
107.
Kissin  B, Charnoff  SM, Rosenblatt  SM.  Drug and placebo responses in chronic alcoholics.  Psychiatr Res Rep Am Psychiatr Assoc. 1968;24:44-60.PubMedGoogle Scholar
108.
Polich  JM, Armor  DJ, Braiker  HB.  Stability and Change in Drinking Patterns: The Course of Alcoholism: Four Years After Treatment. New York, NY: John Wiley & Sons; 1981:159-200.
Original Investigation
May 14, 2014

Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings: A Systematic Review and Meta-analysis

Author Affiliations
  • 1Department of Medicine, University of North Carolina, Chapel Hill
  • 2Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill
  • 3Research Triangle Institute International, Research Triangle Park, North Carolina
  • 4North Carolina Translational and Clinical Sciences Institute, University of North Carolina, Chapel Hill
  • 5Center on Biobehavioral Health Disparities Research, Duke University, Durham, North Carolina
  • 6Gillings School of Global Public Health, University of North Carolina, Chapel Hill
  • 7Department of Psychiatry, University of North Carolina, Chapel Hill
  • 8Bowles Center for Alcohol Studies, University of North Carolina School of Medicine, Chapel Hill
JAMA. 2014;311(18):1889-1900. doi:10.1001/jama.2014.3628
Abstract

Importance  Alcohol use disorders cause substantial morbidity and early mortality yet remain greatly undertreated. Medications are considerably underused.

Objective  To conduct a systematic review and meta-analysis of the benefits and harms of medications (US FDA-approved and others) for adults with alcohol use disorders.

Data Sources  PubMed, Cochrane Library, PsycINFO, CINAHL, EMBASE, FDA website, and clinical trials registries (January 1, 1970, to March 1, 2014).

Study Selection  Two reviewers selected randomized clinical trials (RCTs) with at least 12 weeks’ duration that reported eligible outcomes and head-to-head prospective cohort studies reporting health outcomes or harms.

Data Extraction and Synthesis  We conducted meta-analyses using random-effects models and calculated numbers needed to treat for benefit (NNTs) or harm (NNHs).

Main Outcomes and Measures  Alcohol consumption, motor vehicle crashes, injuries, quality of life, function, mortality, and harms.

Results  We included 122 RCTs and 1 cohort study (total 22 803 participants). Most assessed acamprosate (27 studies, n = 7519), naltrexone (53 studies, n = 9140), or both. The NNT to prevent return to any drinking for acamprosate was 12 (95% CI, 8 to 26; risk difference [RD], −0.09; 95% CI, −0.14 to −0.04) and was 20 (95% CI, 11 to 500; RD, −0.05; 95% CI, −0.10 to −0.002) for oral naltrexone (50 mg/d). The NNT to prevent return to heavy drinking was 12 (95% CI, 8 to 26; RD −0.09; 95% CI, −0.13 to −0.04) for oral naltrexone (50 mg/d). Meta-analyses of trials comparing acamprosate to naltrexone found no statistically significant difference between them for return to any drinking (RD, 0.02; 95% CI, −0.03 to 0.08) or heavy drinking (RD, 0.01; 95% CI, −0.05 to 0.06). For injectable naltrexone, meta-analyses found no association with return to any drinking (RD, −0.04; 95% CI, −0.10 to 0.03) or heavy drinking (RD, −0.01; 95% CI, −0.14 to 0.13) but found an association with reduction in heavy drinking days (weighted mean difference [WMD], −4.6%; 95% CI, −8.5% to −0.56%). Among medications used off-label, moderate evidence supports an association with improvement in some consumption outcomes for nalmefene (heavy drinking days per month: WMD, −2.0; 95% CI, −3.0 to −1.0; drinks per drinking day: WMD, −1.02; 95% CI, −1.77 to −0.28) and topiramate (% heavy drinking days: WMD, −9.0%; 95% CI, −15.3% to −2.7%; drinks per drinking day: WMD, −1.0; 95% CI, −1.6 to −0.48). For naltrexone and nalmefene, NNHs for withdrawal from trials due to adverse events were 48 (95% CI, 30 to 112) and 12 (95% CI, 7 to 50), respectively; risk was not significantly increased for acamprosate or topiramate.

Conclusions and Relevance  Both acamprosate and oral naltrexone were associated with reduction in return to drinking. When directly compared with one another, no significant differences were found between acamprosate and naltrexone for controlling alcohol consumption. Factors such as dosing frequency, potential adverse events, and availability of treatments may guide medication choice.

×